Trial Profile

A Single-centre, open-label, randomised, single-dose, 4-period, crossover study of Pharmacokinetics of ND0612 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa (Primary)
Indications Parkinson's disease
Focus Pharmacokinetics

Most Recent Events

18 Sep 2022 Results (N=16) presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.
28 Jun 2022 Results (n=17) of a study assessing pharmacokinetics-pharmacodynamics relationship between levodopa plasma exposure and motor response in patients with PD treated with ND0612 and adjunct oral PD medication presented at the 8th Congress of the European Academy of Neurology
04 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com